AstraZeneca signs €25m deal to help tackle respiratory disease

23-08-2017

German therapeutics developer Ethris has agreed a €25 million ($29 million) research deal with AstraZeneca focused on developing therapies for respiratory diseases.


AstraZeneca, Ethris, respiratory, MedImmune, mRNA

LSIPR